<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00330460</url>
  </required_header>
  <id_info>
    <org_study_id>20050141</org_study_id>
    <nct_id>NCT00330460</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.</brief_title>
  <official_title>A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Denisty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether in postmenopausal women with low bone
      mineral density, the mean percent change in total hip BMD in subjects receiving denosumab is
      not less than that observed in subjects receiving alendronate sodium by more than a
      pre-specified non-inferiority margin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Hip Bone Mineral Density Percent Change From Baseline at Month 12</measure>
    <time_frame>12 months</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12</measure>
    <time_frame>12 months</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trochanter Bone Mineral Density Percent Change From Baseline at Month 12</measure>
    <time_frame>12 months</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12</measure>
    <time_frame>12 months</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12</measure>
    <time_frame>12 months</time_frame>
    <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1189</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Osteopenia</condition>
  <arm_group>
    <arm_group_label>Alendronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this arm will receive active ALN and placebo denosumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Denosumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive active denosumab and placbo ALN</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate</intervention_name>
    <description>ALN; 70 mg; oral; once weekly</description>
    <arm_group_label>Alendronate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>60 mg; SC; every 6 months</description>
    <arm_group_label>Denosumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - Patient is an ambulatory postmenopausal woman - Patient has BMD value
        that corresponds to a T-score of less than or equal to -2.0 (g/cm2) at the lumbar spine OR
        total hip within range specific to the study protocol. Exclusion Criteria: o Any disorder
        that compromises the ability of the subject to give written informed consent and/or to
        comply with study procedures

          -  Evidence of any of the following per subject report, chart review or central
             laboratory result:

               1. Hyper- or hypothyroidism; however, subjects on stable thyroid hormone replacement
                  therapy may be allowed per the following criteria:

                    -  If TSH level is normal, subject is eligible for the study.

                    -  If TSH level is below normal range, subject is not eligible for the study.

                    -  If TSH level is elevated (&gt; 5.5 mIU/mL to 10.0 mIU/mL), serum T4 should be
                       measured. If serum T4 is within normal range, subject is eligible. If serum
                       T4 is outside of normal range, subject is not eligible for the study.

                    -  If TSH level is above 10.0 mIU/mL, subject is not eligible.

               2. Current hyper- or hypoparathyroidism

               3. Elevated transaminases

                    -  Serum aspartate aminotransferase (AST; serum glutamate-oxaloacetic
                       transaminase [SGOT]) ³ 2.0 x upper limits of normal (ULN)

                    -  Serum alanine aminotransferase (ALT; serum glutamate-pyruvate transaminase
                       [SGPT]) ³ 2.0 x ULN

               4. Significantly impaired renal function as determined by serum creatinine ³ 2.0
                  mg/dL

               5. Current hypo- or hypercalcemia based on the central laboratory reference ranges

               6. Active gastric or duodenal ulcer; history of significant gastrointestinal bleed
                  requiring hospitalization or transfusion, or dyspepsia or gastroesophageal reflux
                  disease that is uncontrolled by medication

               7. Rheumatoid Arthritis, Paget's disease, Cushing's disease, hyperprolactinemia, or
                  cirrhosis of the liver

               8. Known to have tested positive for human immunodeficiency virus, hepatitis C
                  virus, or hepatitis B surface antigen

               9. Malignancy (except fully resected cutaneous basal cell or squamous cell
                  carcinoma, cervical or breast ductal carcinoma in situ) within the last 5 years

              10. Any metabolic bone disease, eg, osteomalacia or osteogenesis imperfecta, which
                  may interfere with the interpretation of the findings

              11. Malabsorption syndrome or any gastrointestinal disorders that are associated with
                  malabsorption

          -  Received any solid organ or bone marrow transplant

          -  Vitamin D deficiency (25(OH) vitamin D level &lt; 12 ng/mL). Vitamin D repletion will be
             permitted and subjects may be re-screened; see Section 7.

          -  Any laboratory abnormality which, in the opinion of the investigator, will prevent the
             subject from completing the study or interfere with the interpretation of the study
             results

          -  Contraindicated or poorly tolerant of ALN therapy; contraindications for ALN therapy
             include:

               1. Abnormalities of the esophagus, which delay esophageal emptying such as stricture
                  or achalasia.

               2. Inability to stand or sit upright for at least 30 minutes.

               3. Hypersensitivity to ALN or other constituents of ALN tablets o Known sensitivity
                  to mammalian cell derived drug products

          -  Known intolerance to calcium supplements

          -  Administration of intravenous bisphosphonate, or fluoride (except for dental
             treatment) or strontium ranelate

          -  Oral bisphosphonate treatment:

               -  ³ 3 months cumulatively in the past 2 years, OR

               -  ³ 1 month in the past year, OR

               -  Any use during the 3-month period prior to randomization

          -  PTH or PTH derivatives (eg, teriparatide) within the last year

          -  Administration of any of the following treatments within 3 months of randomization:

               1. Any SERM (eg, raloxifene)

               2. Tibolone

               3. Anabolic steroids or testosterone

               4. Glucocorticosteroids (³ 5 mg prednisone equivalent per day for more than 10 days)

               5. Systemic (oral, transdermal, topical) hormone replacement therapy (local vaginal
                  estrogen preparation will be allowed)

               6. Calcitonin

               7. Calcitriol or vitamin D derivatives

               8. Other bone active drugs including anti-convulsives (except benzodiazepines) and
                  heparin

               9. Chronic systemic ketoconazole, androgens, ACTH, cinacalcet, aluminum, lithium,
                  protease inhibitors, methotrexate, gonadotropin-releasing hormone agonists

              10. Height, weight or girth which may preclude accurate DXA measurements

          -  Less than 2 lumbar vertebrae (L1-L4) evaluable for DXA measurements

          -  Both hips not evaluable by DXA (eg, history of bilateral hip replacement or pins in
             both hips)

          -  Currently enrolled in or has not yet completed at least 1 month since ending other
             investigational device or drug trial(s), or subject is receiving other investigational
             agent(s)

          -  Any physical or psychiatric disorder which, in the opinion of the investigator, will
             prevent the subject from completing the study or interfere with the interpretation of
             the study results

          -  Evidence of alcohol or substance-abuse within the last 12 months which the
             investigator believes would interfere with understanding or completing the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <results_reference>
    <citation>Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Alvaro-Gracia JM, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J, Bone HG. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009 Jan;24(1):153-61. doi: 10.1359/jbmr.080901.</citation>
    <PMID>18767928</PMID>
  </results_reference>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2006</study_first_submitted>
  <study_first_submitted_qc>May 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2006</study_first_posted>
  <results_first_submitted>June 18, 2010</results_first_submitted>
  <results_first_submitted_qc>June 18, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 19, 2010</results_first_posted>
  <disposition_first_submitted>November 23, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>November 23, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 25, 2009</disposition_first_posted>
  <last_update_submitted>January 20, 2011</last_update_submitted>
  <last_update_submitted_qc>January 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>Osteoporosis</keyword>
  <keyword>Osteopenia</keyword>
  <keyword>AMG 162</keyword>
  <keyword>Fracture - hip</keyword>
  <keyword>Postmenopausal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
    <mesh_term>Alendronate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First Subject Enrolled: 26-Apr-2006 Last Subject Enrolled: 17-Nov-2006</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Alendronate 70 mg QW</title>
        </group>
        <group group_id="P2">
          <title>Denosumab 60 mg Q6M</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="595"/>
                <participants group_id="P2" count="594"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="553"/>
                <participants group_id="P2" count="561"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligibility determined</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Alendronate 70 mg QW</title>
        </group>
        <group group_id="B2">
          <title>Denosumab 60 mg Q6M</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="595"/>
            <count group_id="B2" value="594"/>
            <count group_id="B3" value="1189"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.6" spread="8.3"/>
                    <measurement group_id="B2" value="64.1" spread="8.6"/>
                    <measurement group_id="B3" value="64.4" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="595"/>
                    <measurement group_id="B2" value="594"/>
                    <measurement group_id="B3" value="1189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White or Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="502"/>
                    <measurement group_id="B2" value="502"/>
                    <measurement group_id="B3" value="1004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Hip Bone Mineral Density Percent Change From Baseline at Month 12</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
        <time_frame>12 months</time_frame>
        <population>Randomized subjects who have a nonmissing baseline and at least 1 nonmissing postbaseline evaluation at or prior to month 12. LOCF used as imputation method.</population>
        <group_list>
          <group group_id="O1">
            <title>Alendronate 70 mg QW</title>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg Q6M</title>
          </group>
        </group_list>
        <measure>
          <title>Total Hip Bone Mineral Density Percent Change From Baseline at Month 12</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
          <population>Randomized subjects who have a nonmissing baseline and at least 1 nonmissing postbaseline evaluation at or prior to month 12. LOCF used as imputation method.</population>
          <units>Percent Change from Baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="572"/>
                <count group_id="O2" value="579"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="2.4" upper_limit="2.8"/>
                    <measurement group_id="O2" value="3.5" lower_limit="3.3" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin = -1.22%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alendronate 70 mg QW</title>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg Q6M</title>
          </group>
        </group_list>
        <measure>
          <title>Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
          <units>Percent Change from Baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="571"/>
                <count group_id="O2" value="579"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="3.9" upper_limit="4.5"/>
                    <measurement group_id="O2" value="5.3" lower_limit="5.0" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin = -2.29%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The reported p-value was the one-sided adjusted p-valued based on multiplicity adjustment of the secondary efficacy endpoints</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.7</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trochanter Bone Mineral Density Percent Change From Baseline at Month 12</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alendronate 70 mg QW</title>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg Q6M</title>
          </group>
        </group_list>
        <measure>
          <title>Trochanter Bone Mineral Density Percent Change From Baseline at Month 12</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
          <units>Percent Change from Baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="572"/>
                <count group_id="O2" value="579"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="3.1" upper_limit="3.7"/>
                    <measurement group_id="O2" value="4.5" lower_limit="4.1" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin = -1.65%</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The reported p-value was the one-sided adjusted p-valued based on multiplicity adjustment of the secondary efficacy endpoints</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.6</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alendronate 70 mg QW</title>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg Q6M</title>
          </group>
        </group_list>
        <measure>
          <title>Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
          <units>Percent Change from Baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="572"/>
                <count group_id="O2" value="579"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="1.5" upper_limit="2.1"/>
                    <measurement group_id="O2" value="2.4" lower_limit="2.2" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin = -1.04%</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The reported p-value was the one-sided adjusted p-valued based on multiplicity adjustment of the secondary efficacy endpoints</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.3</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12</title>
        <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alendronate 70 mg QW</title>
          </group>
          <group group_id="O2">
            <title>Denosumab 60 mg Q6M</title>
          </group>
        </group_list>
        <measure>
          <title>Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12</title>
          <description>Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.</description>
          <units>Percent Change from Baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="569"/>
                <count group_id="O2" value="573"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.3" upper_limit="0.8"/>
                    <measurement group_id="O2" value="1.1" lower_limit="0.9" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>The reported p-value was the one-sided adjusted p-valued based on multiplicity adjustment of the secondary efficacy endpoints</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.3</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <desc>The table of Other Adverse Events summarizes the most frequent non-serious occurrences of adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Alendronate 70 mg QW</title>
        </group>
        <group group_id="E2">
          <title>Denosumab 60 mg Q6M</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="593"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Ventricular asystole</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Infected cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Chondromalacia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Cholesteatoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Fibroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Mycosis fungoides</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Ovarian cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Vaginal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Pelvic peritoneal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Urogenital prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Activities of daily living impaired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="593"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="261" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="270" subjects_at_risk="593"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="593"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="593"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="593"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="593"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="586"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="593"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multi-center studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

